Abcam, ab257345, Human ADRBK1 (GRK2) knockout HEK-293T cell lysate

Size: 1Kit
GRK2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-GRK2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein GRK2 also known as G protein-coupled receptor kinase 2 is an important enzyme involved in the regulation of G protein-coupled receptors (GPCRs). It has a molecular weight of approximately 80 kilodaltons. GRK2 is widely expressed in many tissues especially in the heart and brain where it plays an important role in cellular signaling processes. Its primary action is phosphorylating activated GPCRs which leads to receptor desensitization and downregulation modulating cellular responses to stimuli.
Biological function summary
GRK2 acts by coordinating with other proteins to regulate signal transduction pathways. It usually forms a complex with arrestins which prevent further signaling by blocking G protein coupling and directing receptors towards internalization pathways. This kinase acts to modulate receptor activity and maintain cellular homeostasis. GRK2 is essential for preventing overstimulation of cells playing a role in neurobiology and cardiology.
Pathways
GRK2 plays an important role in the adrenergic receptor signaling pathways including the beta-adrenergic and alpha-adrenergic pathways. It participates in the regulation of cardiac output and vascular tone by influencing the response of cells to catecholamines like adrenaline and noradrenaline. Proteins related to GRK2 in these pathways include adrenergic receptor subtypes and arrestin proteins. Voltage-gated calcium channels also interact with GRK2 linking it to calcium signaling pathways vital for muscle contraction and neurotransmitter release.
Research highlights GRK2's involvement in heart failure and hypertension. In heart failure elevated levels of GRK2 correlate with worsened cardiac function due to impaired beta-adrenergic receptor signaling. GRK2 is also linked to the development of hypertension through its effects on vascular smooth muscle cells and blood pressure regulation. Its interaction with proteins like arrestins suggests potential therapeutic targets for these cardiovascular conditions. Understanding and modulating GRK2 activity might offer approaches to treat these disorders.